BMS awarded 2018 ENERGY STAR Partner of the Year Sustained Excellence Award
The company’s environmental efforts honored for the fourth consecutive year.
The US Environmental Protection Agency (EPA) and the US Department of Energy have recognized Bristol-Myers Squibb (BMS) with an ENERGY STAR Partner of the Year Sustained Excellence Award for outstanding efforts to improve the energy efficiency of facilities worldwide. BMS has earned the ENERGY STAR Partner of the Year award for the past 4 consecutive years.
The award confirms BMS’s long-term commitment to environmental responsibility through driving sustainable improvements in energy with a goal of reducing the company use or resources across its drug discovery, development and delivery pipeline.
“We are proud to receive the ENERGY STAR Partner of the Year designation for 4 years, and to increase our recognition with the Sustained Excellence Award,” said Carol Ryerkerk Powell, vice president of Environment, Health, Safety and Sustainability, BMS. “To continue developing innovative medicines for our patients, we have to embrace our responsibility to support our environment, employees and communities. We look forward to our continued partnership with ENERGY STAR to better advance our energy management programs and demonstrate our leadership within the pharmaceutical industry.”
BMS was recognized for the following accomplishments:In addition to the company’s recognition as an ENERGY STAR Partner of the Year, BMS’s R&D site in Hopewell, New Jersey, and the manufacturing site in New Brunswick, New Jersey earned the 2017 Challenge for Industry recognition. The ENERGY STAR Challenge for Industry is a national call-to-action to improve energy efficiency of America’s manufacturers by 10% or more. By taking the ENERGY STAR Challenge, sites set a goal to reduce their energy intensity by 10% within 5 years.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance